Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Essential Thrombocythemia

Clinical Trial at: Texas Oncology - Paris

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Paris

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Paris

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

  • Details

ClinicalTrials.gov ID: NCT03817853
Diagnosis Type: NA
USOR Number: 18265

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Paris

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page